Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection

• Published in: Cancers Vol. 15; no. 10; p. 2866
• Main Authors: Srinivasan Rajsri, Kritika, Roy, Nainita, Chakraborty, Sohini
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.05.2023; MDPI
• Subjects: Acute myeloid leukemia; Cancer; Chemotherapy; Cloning; Cytogenetics; Cytotoxicity; Hemopoiesis; Leukemia; Malignancy; Medical research; Minimal residual disease; Morphology; Mutation; Oncology, Experimental; Pathogenesis; Patients; Physiology; Remission; Remission (Medicine); Review; Risk assessment; Stem cells; Strategic planning (Business); blasts; relapse; immunophenotype; acute myeloid leukemia (AML); multiparametric flow cytometry (MFC); leukemia stem cells (LSCs); measurable/minimal residual disease (MRD)

Acute myeloid leukemia (AML) is a hematological malignancy characterized by an abundance of incompletely matured or immature clonally derived hematopoietic precursors called leukemic blasts. Rare leukemia stem cells (LSCs) that can self-renew as well as give rise to leukemic progenitors comprising t...